NovoCure Limited (NVCR)
(Delayed Data from NSDQ)
$18.08 USD
+0.18 (1.01%)
Updated Aug 19, 2024 04:00 PM ET
After-Market: $18.10 +0.02 (0.11%) 5:18 PM ET
2-Buy of 5 2
D Value C Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.08 USD
+0.18 (1.01%)
Updated Aug 19, 2024 04:00 PM ET
After-Market: $18.10 +0.02 (0.11%) 5:18 PM ET
2-Buy of 5 2
D Value C Growth A Momentum C VGM
Zacks News
NovoCure (NVCR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of 0.00% and -0.44%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Options Traders Expect Huge Moves in NovoCure (NVCR) Stock
by Zacks Equity Research
Investors need to pay close attention to NovoCure (NVCR) stock based on the movements in the options market lately.
NovoCure (NVCR) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of 13.33% and -1.30%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
NovoCure (NVCR) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NovoCure (NVCR) Catches Eye: Stock Jumps 7.4%
by Zacks Equity Research
NovoCure (NVCR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
NovoCure (NVCR) Shares March Higher, Can It Continue
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in NovoCure Limited (NVCR).
NovoCure Limited (NVCR) Looks Good: Stock Adds 7.9% in Session
by Zacks Equity Research
NovoCure (NVCR) was a big mover last session, as the company saw its shares rise more than 7% on the day amid huge volumes.
NovoCure (NVCR) Looks Good: Stock Adds 8.3% in Session
by Zacks Equity Research
NovoCure (NVCR) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
NovoCure (NVCR) Jumps: Stock Rises 10.5%
by Zacks Equity Research
NovoCure (NVCR) was a big mover last session, as the company saw its shares rise over 10% on the day.
Is NovoCure (NVCR) a Great Growth Stock?
by Zacks Equity Research
NovoCure (NVCR) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.